16,050 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by Bokf Na

Bokf Na acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 16,050 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of HALO. Empowered Funds LLC bought a new position in Halozyme Therapeutics in the first quarter worth approximately $755,000. Acadian Asset Management LLC bought a new stake in Halozyme Therapeutics during the 1st quarter valued at $195,000. Hsbc Holdings PLC boosted its position in Halozyme Therapeutics by 117.1% during the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after acquiring an additional 5,448 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 174 shares in the last quarter. Finally, Baird Financial Group Inc. boosted its position in Halozyme Therapeutics by 6.2% during the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 650 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $64.24, for a total transaction of $1,284,800.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $49,322,187.20. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $63.48, for a total value of $103,155.00. Following the transaction, the director owned 38,498 shares of the company’s stock, valued at $2,443,853.04. The trade was a 4.05% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 90,482 shares of company stock worth $6,073,942. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $64.12 on Friday. The stock has a 50-day moving average of $65.86 and a two-hundred day moving average of $68.59. The stock has a market cap of $7.60 billion, a P/E ratio of 25.75, a P/E/G ratio of 0.27 and a beta of 0.89. Halozyme Therapeutics, Inc. has a one year low of $47.50 and a one year high of $82.22. The company has a debt-to-equity ratio of 43.89, a quick ratio of 3.66 and a current ratio of 4.66.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). The company had revenue of $451.77 million for the quarter, compared to analysts’ expectations of $446.13 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The business’s quarterly revenue was up 51.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.26 EPS. As a group, research analysts predict that Halozyme Therapeutics, Inc. will post 7.68 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. HC Wainwright increased their target price on Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Benchmark increased their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Wells Fargo & Company increased their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Six investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $79.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.